Introduction: Hematopoietic stem cell transplantation has become a
well-established treatment for hematologic disorders including acute leukemia.
However, long-term survival rates following this procedure are still extremely
low, due to posttransplantation relapse, infections, and graft-versus-host
disease. We propose that adjunctive Chinese herbal medicine may benefit
posttransplantation patients. In preparation for a randomized clinical trial, we
conducted a pilot trial. Methods and Analysis: Between September
2015 and June 2017, 18 patients were consecutively enrolled at China Medical
University Hospital and followed for up to 1 year. Fresh blood samples were
obtained on a monthly basis, and immune reconstitution was analyzed. In addition
to the standard-care treatment administered by their oncologist, a number of
patients also received a Chinese herbal formula (Sheng-Yu-Tang) for up to 6
months. Results were used to improve on study protocol and estimate required
sample size for a future randomized trial. Ethics and
Dissemination: Study protocol was approved by the institutional
review board of China Medical University Hospital (DMR-105-005), and all
participants provided informed consent.